Introduction: What they say
A recent study from Research Center for Neurobiology and Department of Neurobiology, Xuzhou Medical College, 209 Tongshan Road, Xuzhou, Jiangsu 221004, PR China; and School of Public Health, Xuzhou Medical College, PR China shows that “HO-1 attenuates hippocampal neurons injury via the activation of BDNF-TrkB-PI3K/Akt signaling pathway in stroke.“ This study was published, in the July 2 2014 issue of the journal Brain Research, by Prof Dong, Qi, and others.
Another study from the Department of Pharmacology, Second Military Medical University, Shanghai, China; Department of Science and Education, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China; and Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China (C.-Y.M.) shows that “Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade” This study was published, in the June 9 2015 issue of the journal Stroke, by Prof Miao CY, Zhao Y, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: AP-1(Activator protein-1)-inducing compounds may protect you against stroke: AP-1 attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT
From research findings to therapeutic opportunity:
AP-1 (Activator protein-1), consists of c-Jun and c-fos, among other AP-1 related proteins, has been shown to play a role in stroke. However, the mechanism of action remains largely obscure. This study suggests, first the first time, AP-1-based therapy, with detailed mechanistic insights, for stroke.
AP-1, by increasing the expression of its target genes, it may: (1) increase the expression of BDNF and NAMPT (Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide); (2) augment neuronal–BDNF-TrkB-PI3K/Akt–survival pathway; (3) increase sirtuins expression; (4) enhance neural stem cells; (5) promote neural functional recovery; (6) attenuate cerebral /Ischemia-reperfusion injury; (7) inhibit neuronal apoptosis; (8) improve learning and memory; and (9) attenuate neurological deficits (Figs.1-2). [easy_payment currency=”USD”]
Together, this study suggests that AP-1-inducing compounds may alleviate stroke, and other neurodegenerative diseases (such as multiple sclerosis, cerebral ataxia etc.), promote brain repair and extend the lifespan of an individual. Thus, AP-1-inducing compounds, either alone or in combination with other drugs,” may be used to treat stroke and other neurological deficits.
Details of the idea posted:
Idea Proposed/Formulated by Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does AP-1 increase the expression of BDNF and NAMPT?
For purchase and payment details, you may reach us at firstname.lastname@example.org
# Research cooperation
Citation: Boominathan, L., AP-1(Activator protein-1)-inducing compounds may protect you against stroke: AP-1 attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT, 25/November/2018, 8.15 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com